This is repository of my old source code which isn't updated any more. Go to git.rot13.org for current projects!
ViewVC logotype

Contents of /news/33.html

Parent Directory Parent Directory | Revision Log Revision Log

Revision 1.2 - (show annotations)
Sat Mar 3 08:32:51 2001 UTC (19 years, 7 months ago) by dpavlin
Branch: MAIN
Changes since 1.1: +1 -1 lines
File MIME type: text/html
added missing mailto:

1 <p align="center"><b>PLIVA Receives a License from BAYER AG for a New Chemical
2 Entity for the Treatment of Fungal Infections</b></p>
3 <p> PLIVA d.d. ('PLIVA') announced today that it has received a license for a
4 new chemical entity for the treatment of fungal infections from BAYER AG, Germany,
5 a compound in its final stage of pre-clinical trials.</p>
6 <p> The compound BAY 10-8888, part of the family of beta-amino acids, was identified
7 at Bayer during an effort to find novel treatment options for fungal infections
8 caused by the Candida yeast. Candida infections are prevalent in patients suffering
9 from AIDS or those undergoing cancer chemotherapy and/or immunosuppressive therapy
10 treatment e.g. for organ transplantation and vaginal mycosis. Furthermore, Candida
11 has been identified as the fourth most common pathogen in nosocomial infections
12 in hospitalized patients. </p>
13 <p>The total market size for anti-fungals amounted to USD 2.6 billion in 1999.
14 Only the azole compound class, which was developed in the early 80s and now
15 dominates over 60% of the market, is currently available for oral treatment
16 of the aforementioned diseases,. Due to the increasing prevalence of Candida
17 infections and the frequent use of azoles in treatment, however, severe resistance
18 problems have arisen in recent years.</p>
19 <p> The compound BAY 10-8888 displays high activity both in vitro and in vivo
20 against Candida infections. Due to its novel mode of action, the compound additionally
21 combats azole resistant pathogens. According to the data generated in various
22 species, the compound exerts highly favorable pharmacokinetic behavior, indicating
23 a single daily dose for patients. The compound would be the first novel class
24 for the oral treatment of yeast infections following the introduction of azoles
25 in the 70s. </p>
26 <p>Due to a shift in its business strategy, BAYER decided to leave the anti-fungal
27 segment and make the compound available for licensing. In its licensing agreement
28 with BAYER, PLIVA received worldwide development and marketing rights to the
29 product under non-disclosed terms.</p>
30 <p> "PLIVA continues to undertake strong steps in an effort to further expand
31 its position in the anti-infective business area," comments Mr. Radan Spaventi,
32 Chief Scientific Officer of PLIVA. "In addition to our successful in-house research
33 efforts in anti-bacterials, BAY 10-8888 will allow us to further broaden our
34 product portfolio in anti-infectives. We believe that this product will represent
35 a significant contribution to the anti-fungal market, given its activity against
36 strains resistant to existing drugs." </p>
37 <p>PLIVA has renamed the compound PLD-118, according to its classification scheme,
38 and plans to start clinical development this year. In line with its R&D strategy,
39 PLIVA intends to establish a relationship with a global partner for the development
40 and marketing of the product after completion of Phase I and/or Phase II clinical
41 trials. PLIVA's total R&D expenditures in 2000 are expected to reach about HRK
42 330 million. </p>
43 <p>For further information, please contact: </p>
44 <p>Erika Kaspar<br>
45 Vice President, Communications and Corporate Affairs <br>
46 Tel: 385 1 6120 755<br>
47 Fax: 385 1 6114 413<br>
48 E-mail: <a href="mailto:erika.kaspar@pliva.hr">Erika.Kaspar@pliva.hr</a></p>
49 <p> Marija Mandic <br>
50 Financial Analyst<br>
51 Tel: 385 1 6160 355 <br>
52 Fax: 385 1 6120 634<br>
53 E-mail: <a href="mailto:marija.mandic@pliva.hr">Marija.Mandic@pliva.hr</a> </p>

  ViewVC Help
Powered by ViewVC 1.1.26